An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primatesResearch in context

Summary: Background: Angiopoietin-like protein 4 (ANGPTL4) inhibition is a promising approach to manage atherogenic dyslipidaemia and residual atherosclerotic cardiovascular disease (ASCVD) risk. Human ANGPTL4 loss-of-function (LoF) is associated with reduced plasma triglyceride (TG), remnant chole...

詳細記述

書誌詳細

主要な著者:	Beryl B. Cummings, Page R. Bouchard, Mark N. Milton, Peter F. Moesta, Vyas Ramanan, John W. Trauger, Eleftheria Maratos-Flier, Andrei Voznesensky, Igor Splawski, Amitabh V. Nimonkar, Keith DiPetrillo, Daniel LaSala, Meihui Pan, Meghan M. Flaherty, Francois Huet, Sukhdeep K. Sahambi, Jijun Dong, Deborah Knee, Regis Cebe, Thomas Huber, Joshua Lehrer-Graiwer, Rebecca A. Juliano, Ethan J. Weiss
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2025-07-01
シリーズ:	EBioMedicine
主題:	MAR001 ANGPTL4 Triglyceride Remnant cholesterol Non-human primates Safety
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2352396425001926
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!